Presentation of SFX-01 Data at ECTRIMS 2016

RNS Number : 3582J

Evgen Pharma PLC

08 September 2016

 

For immediate release	8 September 2016

 

 

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Presentation of SFX-01 Data at ECTRIMS 2016

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that the results of its preclinical study of SFX-01 in various models of the relapsing remitting form of multiple sclerosis will be presented on Friday 16 September 2016 at the 32^nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London. The study focused on the comparison of SFX-01 with dimethyl fumarate, the active principle in BG-12 which is marketed as Tecfidera^®.

The data from these preclinical studies are embargoed for poster presentation at the conference. A late-breaking abstract of the poster will be made available on the ECTRIMS website on Monday 12 September 2016.

The poster is entitled Efficacy of SFX-01, a sulforaphane-based drug in experimental autoimmune encephalomyelitis and has the poster number P1658. Its authors are Dr Ian Galea (Associate Professor in Experimental Neurology, Faculty of Medicine, University of Southampton), Dr Ian Copple (Lecturer, Institute of Translational Medicine, University of Liverpool) and Dr David Howat (Evgen's Chief Development Officer).

The concluding statement from the poster is: "SFX-01 appears to be superior to BG-12 in the therapeutic EAE model. SFX-01 appears to exert maximum effects later in the course of the disease by enabling superior neurological recovery in the chronic stage after relapse. SFX-01 is a promising drug candidate in MS, and warrants further investigation."

Once presented, a copy of the poster will be made available on Evgen Pharma's website, www.evgen.com.

Dr Stephen Franklin, CEO of Evgen Pharma, commented: "We are delighted that our preclinical multiple sclerosis data has been accepted as a late breaking abstract at this year's ECTRIMS conference.  The preclinical study compared Evgen Pharma's SFX-01 against dimethyl fumarate, the active within Biogen's Tecfidera^® which is currently the main oral therapy for the relapsing-remitting form of multiple sclerosis with annualised sales of approximately US$4bn.  This early stage comparative data is encouraging and we intend to accelerate the commercial appraisal of this opportunity with a view to updating shareholders later this year."

The 2016 ECTRIMS conference is being held on 14-17 September at ExCel London, One Western Gateway, Royal Victoria Dock, London E16 1X.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Cowles, Stephanie Watson		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance) John Howes, Rob Rees (Corporate Broking)		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  For further information please visit www.evgen.com

 

END

 

 

MSCEALNPEAKKEFF